Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Perry

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Journal of Digestive Diseases|April 24, 2020
The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort studyKerri Glassner, Ayah Oglat, Antonio Duran, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 19, 2014
Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG StudyBorje Darpo, Meijian Zhou, Jessica Matthews, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 11, 2014
Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG StudyBorje Darpo, Meijian Zhou, Jessica Matthews, et al.
Diabetologia|September 12, 2014
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylureaPeter N Weissman, Molly C Carr, June Ye, et al.
Diabetes Care|June 6, 2014
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metforminBo Ahrén, Susan L Johnson, Murray Stewart, et al.
Journal of Digestive Diseases|April 10, 2024
Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumabMohammed Ansari, Kerri Glassner, Malcolm Irani, et al.
Chemosphere|May 14, 2020
Mitochondrial-related effects of pentabromophenol, tetrabromobisphenol A, and triphenyl phosphate on murine BV-2 microglia cellsChristine Bowen, Gabrielle Childers, Caroline Perry, et al.
Communications Biology|April 9, 2024
Visualizing subcellular changes in the NAD(H) pool size versus redox state using fluorescence lifetime imaging microscopy of NADHAngela Song, Nicole Zhao, Diana C Hilpert, et al.
Infectious Diseases and Therapy|October 22, 2022
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female ParticipantsCaroline Perry, Mohammad Hossain, Marcy Powell, et al.
Diabetologia|November 19, 2015
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exerciseMichael A Nauck, Murray W Stewart, Christopher Perkins, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Journal of Digestive Diseases|April 24, 2020
The use of combination biological or small molecule therapy in inflammatory bowel disease: A retrospective cohort studyKerri Glassner, Ayah Oglat, Antonio Duran, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|July 19, 2014
Erratum to: Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG StudyBorje Darpo, Meijian Zhou, Jessica Matthews, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 11, 2014
Albiglutide Does Not Prolong QTc Interval in Healthy Subjects: A Thorough ECG StudyBorje Darpo, Meijian Zhou, Jessica Matthews, et al.
Diabetologia|September 12, 2014
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylureaPeter N Weissman, Molly C Carr, June Ye, et al.
Diabetes Care|June 6, 2014
HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metforminBo Ahrén, Susan L Johnson, Murray Stewart, et al.
Journal of Digestive Diseases|April 10, 2024
Therapeutic drug monitoring in inflammatory bowel disease patients on vedolizumabMohammed Ansari, Kerri Glassner, Malcolm Irani, et al.
Chemosphere|May 14, 2020
Mitochondrial-related effects of pentabromophenol, tetrabromobisphenol A, and triphenyl phosphate on murine BV-2 microglia cellsChristine Bowen, Gabrielle Childers, Caroline Perry, et al.
Communications Biology|April 9, 2024
Visualizing subcellular changes in the NAD(H) pool size versus redox state using fluorescence lifetime imaging microscopy of NADHAngela Song, Nicole Zhao, Diana C Hilpert, et al.
Infectious Diseases and Therapy|October 22, 2022
Design of Two Phase III, Randomized, Multicenter Studies Comparing Gepotidacin with Nitrofurantoin for the Treatment of Uncomplicated Urinary Tract Infection in Female ParticipantsCaroline Perry, Mohammad Hossain, Marcy Powell, et al.
Diabetologia|November 19, 2015
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exerciseMichael A Nauck, Murray W Stewart, Christopher Perkins, et al.
Pageof 4